{"id":"W4405897743","doi":"10.1212/wnl.0000000000210153","title":"Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis","year":2024,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Sanofi Genzyme; Mitsubishi Tanabe Pharma Corporation; Genentech; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Horizon Pharmaceuticals; GW Pharmaceuticals; TG Therapeutics; CSL Behring; AveXis; Biogen; Celgene; EMD Serono; University of Pennsylvania; Prothena; Alexion Pharmaceuticals; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi; U.S. Department of Defense","keywords":"Multiple sclerosis; Relapsing remitting; Medicine; Outcome (game theory); Oncology; Internal medicine; Psychiatry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09404637,0.0006185636,0.001900047,0.001355902,0.0004355284,0.001815576,0.0008489147,0.0009728117,0.001945393],"category_scores_gemma":[0.07999105,0.0002249948,0.003194225,0.001524517,0.001000236,0.0016114,0.001436278,0.001987461,0.0002395987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005709455,"about_ca_system_score_gemma":0.0009913727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002458652,"about_ca_topic_score_gemma":0.0004884227,"domain_scores_codex":[0.9040555,0.08100029,0.006158323,0.004199074,0.003765272,0.0008215785],"domain_scores_gemma":[0.873444,0.09044376,0.02460186,0.006351967,0.003773803,0.001384569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2479726,0.001175679,0.5394814,0.005608902,0.05203594,0.0002640266,0.0008463925,0.01148423,0.003553543,0.005772336,0.004772189,0.1270328],"study_design_scores_gemma":[0.02612235,0.0665666,0.7969951,0.001541094,0.02293276,0.001163965,0.0005275444,0.04798571,0.005479312,0.01303711,0.01737189,0.000276498],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9553802,0.01478891,0.01706244,0.001080725,0.0004212123,0.002133105,0.003105293,0.0001793897,0.005848822],"genre_scores_gemma":[0.9921978,0.0003489586,0.003975843,0.0002577438,0.0001188012,0.001868706,0.0008694666,0.0000327379,0.0003299918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09404637,"threshold_uncertainty_score":0.4973707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1254690276954017,"score_gpt":0.3851808798486684,"score_spread":0.2597118521532666,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}